FDA Accepts Milestone Pharmaceuticals' New Drug Application For Cardamyst (Etripamil) Nasal Spray, To Manage Paroxysmal Supraventricular Tachycardia Prescription Drug User Fee Act Is 10 Months From The Acceptance Date Of May 26, 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Milestone Pharmaceuticals' New Drug Application for Cardamyst (Etripamil) nasal spray, aimed at managing paroxysmal supraventricular tachycardia. The Prescription Drug User Fee Act date is set for May 26, 2024.
May 29, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA has accepted Milestone Pharmaceuticals' New Drug Application for Cardamyst (Etripamil) nasal spray, which is designed to manage paroxysmal supraventricular tachycardia. The Prescription Drug User Fee Act date is set for May 26, 2024.
The acceptance of the New Drug Application by the FDA is a significant milestone for Milestone Pharmaceuticals. This regulatory progress is likely to positively impact the stock price in the short term as it brings the company closer to potentially launching a new product.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100